It can be concluded that chemotherapy combined with immunotherapy should be recommended for diffuse-type GC patients, while chemoradiotherapy combined with HER2-targeted therapy is more conducive to intestinal-type patients. This evidence concerns the gene ERBB2 and gastric cancer.